%0 Journal Article
%T Amino-Functionalized Silica Nanoparticles: In Vitro Evaluation for Targeted Delivery and Therapy of Pancreatic Cancer
%A Abbey Y. Kardys
%A Dhruba J. Bharali
%A Shaker A. Mousa
%J Journal of Nanotechnology
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/768724
%X We report a method of synthesis and optimization of amino-functionalized silica nanoparticles (SiNPs) and their in vitro evaluation as targeted delivery vehicles for the potential treatment of pancreatic cancer. SiNPs can efficiently encapsulate doxorubicin and can be attached to a targeting moiety such as anti-Claudin-4 (CLN4). The preferential uptake in pancreatic cancer cells, where CLN4 is overexpressed, of SiNPs when conjugated to CLN4 antibody (compared to nonconjugated SiNPs) was confirmed by confocal microscopy. SiNPs encapsulating doxorubicin had greater efficacy in MTT assays than free doxorubicin, and when conjugated to CLN4, the efficacy was dramatically increased (at 1£¿¦ÌM). No apparent carrier toxicity was observed when void SiNPs were used. SiNPs carrying a chemotherapeutic drug have the potential to be used as a targeted therapy for lethal cancers, such as pancreatic cancer. Also, incorporation of fluorescent probes in these SiNPs creates the possibility of their use as an imaging probe for diagnostic purposes. 1. Introduction Cancer is still one of the most lethal diseases and one of the leading causes of death worldwide. Although there have been significant improvements in treating many cancers including breast, prostate, and lung with advances in medical technology, improvements in pancreatic cancer treatment have lagged behind. In the United States, pancreatic cancer is the fourth leading cause of cancer-related death. Aggressive disease progression and difficulties in early detection (before it metastasizes) are the two major factors that contribute to the ~95% death rate for patients suffering from pancreatic cancer. In most cancer treatments, the key to success relies mainly on early diagnosis, but in the case of pancreatic cancer currently available diagnosis technology is largely ineffective until the cancer progresses to late stages [1]. According to the American Association for Cancer Research, in 2012 there were an estimated 43,920 new cases of pancreatic cancer expected to occur, with 37,390 deaths [1]. Conventional treatment, which relies mainly on highly invasive chemotherapy, radiation, and surgery, has failed to impact the pancreatic cancer death rate because pancreatic cancer is resistant to most of the currently available chemo- and radiation therapies, and surgical removal of the primary tumor is fruitless owing to its high tendency to metastasize to distant organs. This is particularly true for individuals known to be ¡°at risk¡± for developing pancreatic cancer because they have an inherited predisposition to it [2¨C5].
%U http://www.hindawi.com/journals/jnt/2013/768724/